CNOT6

Across TCGA pan-cancer cohorts, CNOT6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CNOT6 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CNOT6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CNOT6 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CNOT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.989	0.465	.038	6	view →
HNSC	DFS	Median	IV	0.420	0.889	.038	2	view →
LUAD	DFS	Median	III,IV	0.934	0.696	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CNOT6–LSCC (OS)

Open the LSCC breakdown →